Filter Results:
- Full text PDF available (15)
Publication Year
1962
2018
- This year (36)
- Last 5 years (55)
- Last 10 years (103)
Publication Type
Co-author
Journals and Conferences
Organism
Learn More
- Fumihiro F. Shoji, A. Haro, +4 authors Yoshihiko Maehara
- The Annals of thoracic surgery
- 2010
BACKGROUND
The 5-year survival rate of pathologic stage IA non-small cell lung cancer (NSCLC) is excellent; however, up to 10% of patients with pathologic stage IA NSCLC still relapse postoperatively… (More)
- Fumihiro F. Shoji, Riichiroh Maruyama, Tatsuro Okamoto, Hiroshi Wataya, Kenichi Nishiyama, Yukito Ichinose
- World journal of surgical oncology
- 2005
BACKGROUND
Malignant schwannoma of the upper mediastinum originating from the vagus nerve is extremely rare.
CASE PRESENTATION
A 46-year-old female was admitted for a left cervical mass which was… (More)
- Tomoyoshi Takenaka, Tokujiro Yano, +7 authors Yoshihiko Maehara
- Lung cancer
- 2010
BACKGROUND
Excision repair cross-complementation group 1 (ERCC1) is the lead enzyme in the nucleotide excision repair process. Two polymorphisms of ERCC1, T19007C (rs11615) and C8092A (rs3212986),… (More)
- Kazuki Takada, Tatsuro Okamoto, +11 authors Yoshihiko Maehara
- Journal of thoracic oncology : official…
- 2016
INTRODUCTION
The clinicopathological features of carcinomas expressing programmed death ligand 1 (PD-L1) and their associations with common driver mutations, such as mutations in the EGFR gene, in… (More)
- Tomoyoshi Takenaka, Ichiro Yoshino, +5 authors Yoshihiko Maehara
- International journal of cancer
- 2007
DNA repair enzyme expression in tumor cells possibly affects sensitivity to anti-cancer agents. The aim of this study was to determine the relationship between expression status of DNA repair enzymes… (More)
- Kazuki Takada, Gouji Toyokawa, +10 authors Yoshihiko Maehara
- Clinical lung cancer
- 2017
BACKGROUND
Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have been identified as novel targets for immunotherapy, with anti-PD-1 therapy currently the standard treatment… (More)
- Fumihiro F. Shoji, Ichiro Yoshino, +7 authors Yoshihiko Maehara
- Cancer
- 2007
BACKGROUND
The presence of epidermal growth factor receptor (EGFR) gene mutations is a good indicator of the clinical efficacy of gefitinib in patients with nonsmall cell lung cancer. It was recently… (More)
- Fumihiro F. Shoji, Ichiro Yoshino, Takuro Kometani, Hidetaka Yamamoto, Yoshihiko Maehara
- The Journal of thoracic and cardiovascular…
- 2007
- Tokujiro Yano, Yosuke Morodomi, +5 authors Yoshihiko Maehara
- Fukuoka igaku zasshi = Hukuoka acta medica
- 2008
- Kazuki Takada, Tatsuro Okamoto, +9 authors Yoshihiko Maehara
- Lung cancer
- 2017
BACKGROUND
Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway-targeted immunotherapy has become the standard option of care in the management of lung cancer. The expression… (More)